An interventional study of FertilOMed Diet and MedDiet in PCOS- Polycystic Ovary Syndrome, Nutrition Intervention and Nutrition Assessment, sponsored by Ondokuz Mayıs University. Enrolling by invitation at 1 site in Turkey (Türkiye). Open to female participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Ondokuz Mayıs University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Polycystic Ovary Syndrome with a site in Turkey — 14 open to participants now, 15 under way, none of them phase 3. Polycystic Ovary Syndrome · Turkey.
Among the 72 studies in Polycystic Ovary Syndrome with a site in Turkey, this one is the 21st largest by planned enrollment of the 29 interventional ones that give a count, is one of 7 that started in 2025, is one of 26 with no phase, reaches primary completion later than 14 of the 14 other live ones, and was the 56th registered.
959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →14 of the 72 studies in Polycystic Ovary Syndrome with a site in Turkey are open now. Recruiting first, the newest first:
Atlas University · Sites in Turkey
Ages 18–45 · Women only
Istanbul Health and Technology University · Sites in Turkey
Ages 18–40 · Women only · Healthy volunteers
Dicle University · Sites in Turkey
Ages 20–40 · Women only
Ege University · Sites in Turkey
Ages 18–40 · Women only
Marmara University · Sites in Turkey
Ages 18+ · Women only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 20 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 70 across 700 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 54 across the 29 interventional studies, 90 across the 43 observational. Of the 50 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 72 has an industry lead sponsor. The 10 most frequent:
Ondokuz Mayıs University is the lead sponsor of 281 studies on the registry; 64 are open to participants now.
Ondokuz Mayıs University has 1 study filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Polycystic Ovary Syndrome with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07896642Istanbul Health and Technology UniversityBrown Adipose Tissue Modulation in Polycystic Ovary Syndrome Using Infrared Thermography | 2026-12 |
| NCT07509762Biruni UniversityExercise Programs in Women With PCOS | 2027-01-15 |
| NCT07871851Inonu UniversityInvestigation of the Effectiveness of Spinal Stabilization Exercises Added to Aerobic Exercise in Women With Polycystic Ovary Syndrome | 2027-01-20 |
| NCT07342946Atlas UniversityThe Effects of the Mediterranean Diet and Synbiotics in Polycystic Ovary Syndrome | 2027-04-01 |
| NCT07731373Kayseri City HospitalBiomarker Panel for PCOS-Associated Liver Steatosis in Adolescent Girls (COMPASS-pedPCOS) | 2027-04-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 72 studies in Polycystic Ovary Syndrome with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate whether different dietary models can improve clinical, metabolic, hormonal, anthropometric, and quality-of-life parameters in women with polycystic ovary syndrome (PCOS).
The main questions it aims to answer are:
Participants: Women diagnosed with PCOS who meet the inclusion criteria and volunteer to participate will be included in the study.
Interventions:
Participants will be randomly assigned to one of the following groups:
This study will include volunteer female individuals who have applied to the Gynecology and Obstetrics outpatient clinic of the Gynecology and Obstetrics Department of Samsun Training and Research Hospital, diagnosed with PCOS by a physician, and selected according to inclusion and exclusion criteria. Women who meet the criteria will be informed about the study's objectives and methodology, and those who agree to participate will be asked to sign a consent form. Individuals will be assigned to control and intervention groups, matched by age and BMI. Care will be taken to ensure that the groups are matched by age and body mass index (BMI). At the beginning of the study, a questionnaire containing sociodemographic information, general health information, dietary habits, physical activity status, sleep habits, morningness-eveningness scale, PCOS-50 Quality of Life scale, Beck depression scale, SF-36 scale, and food consumption record will be administered to the individuals via face-to-face interviews by the researcher. Initial anthropometric measurements of the female volunteers will be taken by the researcher using appropriate techniques. Additionally, biochemical findings will be obtained from hospital records at the beginning and end of the study. Volunteers, matched by age and BMI, were included in the control and intervention groups and will be followed for 12 weeks. Individuals in the control group will receive only medical treatment throughout the study period. They will be free to make food choices without energy restrictions (ad libitum). No dietary intervention will be implemented. Individuals in the intervention groups will receive ad libitum nutrition education and brochures about the diet's content, in addition to their medical treatment. Individuals in both intervention groups will not be restricted in their daily dietary energy intake.
During the 12-week follow-up period, individuals will be closely monitored through mobile applications and routine follow-up visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants follow Mediterranean Diet
Other: MedDiet
Participants follow Fertility-Optimized Mediterranean Diet
Other: FertilOMed Diet
Participants receive standard dietary recommendations
FertilOMed Diet (Experimental): Participants will follow the FertilOMed Diet, which is based on the standard Mediterranean Diet guidelines, with required consumption of specific foods and adherence to recommended food group portions. Dietary adherence will be monitored through food diaries and follow-up consultations.
Mediterranean Diet (Active Comparator): Participants will follow a standard Mediterranean Diet for the duration of the study. Dietary adherence will be monitored through food diaries and follow-up consultations.
Changes in Hormonal Profile
The primary outcome measure of this study is to evaluate holistic changes in the reproductive-metabolic profile of individuals with PCOS following the dietary intervention. This composite outcome includes coordinated changes in hormonal balance (e.g., FSH, LH, Estradiol, Progesterone, 17-Hydroxyprogesterone, DHEAS, T4, TSH, Prolactin, SHBG, AMH, Total Testosterone, and FAI). All parameters will be measured at baseline and after the 12-week dietary intervention, and changes will be analyzed to determine the overall impact of the applied dietary model. These parameters will be obtained by scanning the participants' routine results from their file information.
Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.
Changes in Metabolic Profile
The primary outcome measure of this study is to evaluate holistic changes in the reproductive-metabolic profile of individuals with PCOS following the dietary intervention. This composite outcome includes coordinated changes in metabolic profile (e.g., , AST, ALT, Hemogram, D Vitamini, B12 Vitamini, SHBG, HbA1c, AMH, Total Testosteron, Glukoz, İnsülin, HOMA IR, HDL, LDL, Trigliserit, Total Kolesterol). All parameters will be measured at baseline and after the 12-week dietary intervention, and changes will be analyzed to determine the overall impact of the applied dietary model. These parameters will be obtained by scanning the participants' routine results from their file information.
Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.
Changes in Oxidative Stress
The primary outcome measure of this study is to evaluate holistic changes in the reproductive-metabolic profile of individuals with PCOS following the dietary intervention. This composite outcome includes coordinated changes in hormonal balance (e.g.,TAC, Vit C, SOD, Catalase, Glutathione Peroxidase (GPx) and Malondialdehyde (MDA)). All parameters will be measured at baseline and after the 12-week dietary intervention, and changes will be analyzed to determine the overall impact of the applied dietary model. These parameters will be determined by performing validated commercial ELISA kits in accordance with the manufacturer's instructions and evaluating with a microplate reader.
Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.
Changes in Body Mass Index (BMI)
Body mass index (BMI) will be calculated using weight (kg) and height (m²). Although weight and height will be measured, only BMI (kg/m²) will be reported as the outcome variable. Changes in BMI from baseline to the end of the 12-week dietary intervention will be evaluated to assess the impact of the intervention on anthropometric status.
Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.
Change in Waist Circumference
Anthropometric parameter used to assess central adiposity.
Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.
Change in Hip Circumference
Anthropometric parameter used to evaluate lower-body fat distribution.
Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.
Change in Waist-to-Hip Ratio
Derived anthropometric index reflecting fat distribution.
Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.
Change in Neck Circumference
Anthropometric indicator associated with upper-body fat distribution.
Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.
Change in Body Fat Percentage
Body fat percentage will be measured using the TANITA BC-545N bioelectrical impedance device under standardized conditions (8-hour fasting, light clothing, removal of metal/electronic items). Changes from baseline to Week 12 will be assessed.
Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.
Change in Lean Mass
Lean mass will be measured using the TANITA BC-545N device under standardized measurement conditions. Changes from baseline to Week 12 will be evaluated.
Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.
Change in Muscle Mass
Muscle mass will be assessed via TANITA BC-545N using standardized fasting and measurement procedures. Change from baseline to Week 12 will be recorded.
Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.
Change in Total Body Water
Total body water will be assessed via TANITA BC-545N. Device output will be reported as percentage (%) or liters (L), depending on the measurement format. Changes from baseline to Week 12 will be evaluated.
Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.
Change in Depression Symptoms (Beck Depression Inventory)
Depressive symptoms will be evaluated using the Beck Depression Inventory (BDI).
Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.
Change in PCOS-Specific Quality of Life (PCOSQ-50)
The PCOSQ-50 questionnaire assesses PCOS-specific quality of life across multiple domains.
Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.
Change in Health-Related Quality of Life (SF-36)
The SF-36 evaluates general health-related quality of life.
Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Nov 2027, 23 months after the start.
Of 205 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 23 months is above that.
Counting every sponsor, half of 220 studies reached it within 17 months; a quarter within 7 and three quarters within 37.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Mar 2026 → Nov 2027 and completion May 2026 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.